[go: up one dir, main page]

JPWO2020117968A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020117968A5
JPWO2020117968A5 JP2020572440A JP2020572440A JPWO2020117968A5 JP WO2020117968 A5 JPWO2020117968 A5 JP WO2020117968A5 JP 2020572440 A JP2020572440 A JP 2020572440A JP 2020572440 A JP2020572440 A JP 2020572440A JP WO2020117968 A5 JPWO2020117968 A5 JP WO2020117968A5
Authority
JP
Japan
Prior art keywords
mutation
amino acid
functionally equivalent
substitution
position functionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020572440A
Other languages
Japanese (ja)
Other versions
JP2022511206A (en
JP7527208B2 (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064524 external-priority patent/WO2020117968A2/en
Publication of JP2022511206A publication Critical patent/JP2022511206A/en
Publication of JPWO2020117968A5 publication Critical patent/JPWO2020117968A5/ja
Application granted granted Critical
Publication of JP7527208B2 publication Critical patent/JP7527208B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (20)

９°Ｎ ＤＮＡポリメラーゼアミノ酸配列配列番号１と少なくとも８０％同一であるアミノ酸配列を含む組換えＤＮＡポリメラーゼであって、前記ＤＮＡポリメラーゼは、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中のＴｈｒ３４９と機能的に等価な位置でのアミノ酸置換変異を含み、Ｔｈｒ３４９と機能的に等価な位置での前記置換変異が、極性、荷電または非荷電アミノ酸への変異を含む、組換えＤＮＡポリメラーゼ。 A recombinant DNA polymerase comprising an amino acid sequence that is at least 80% identical to the 9°N DNA polymerase amino acid sequence SEQ ID NO: 1, said DNA polymerase being functionally equivalent to Thr349 in said 9°N DNA polymerase amino acid sequence A recombinant DNA polymerase comprising an amino acid substitution mutation at a position that is functionally equivalent to Thr349, wherein said substitution mutation at a position functionally equivalent to Thr349 comprises mutation to a polar, charged or uncharged amino acid . Ｔｈｒ３４９と機能的に等価な位置での前記置換変異が、ＳｅｒまたはＡｓｎへの変異を含む、請求項１に記載のポリメラーゼ。 2. The polymerase of claim 1 , wherein said substitution mutation at a position functionally equivalent to Thr349 comprises a mutation to Ser or Asn. Ｔｈｒ３４９と機能的に等価な位置での前記置換変異が、Ｌｙｓへの変異を含む、請求項１に記載のポリメラーゼ。 2. The polymerase of claim 1 , wherein said substitution mutation at a position functionally equivalent to Thr349 comprises a mutation to Lys. 前記ポリメラーゼが、少なくとも２つ、少なくとも３つ、または４つのアミノ酸置換変異を含み、さらなる置換変異が、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中のＡ２８１、Ｆ２８３、またはＴｒｐ３９７から選択されるアミノ酸と機能的に等価な位置でのものである、請求項１～３のいずれか一項に記載のポリメラーゼ。 said polymerase comprises at least 2, at least 3, or 4 amino acid substitution mutations, wherein additional substitution mutations are functional with an amino acid selected from A281, F283 , or Trp397 in said 9°N DNA polymerase amino acid sequence; The polymerase according to any one of claims 1 to 3 , which is at a position equivalent to . 前記ポリメラーゼが、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中のアミノ酸Ｍｅｔ１２９、Ａｓｐ１４１、Ｇｌｕ１４３、Ｃｙｓ２２３、Ｌｅｕ４０８、Ｔｙｒ４０９、Ｐｒｏ４１０、Ａｌａ４８５、Ｔｙｒ４９７、Ａｒｇ２４７、Ｇｌｕ５９９、およびＨｉｓ６３３と機能的に等価な位置でのアミノ酸置換変異をさらに含む、請求項１、３または４に記載のポリメラーゼ。 said polymerase has amino acid substitutions at positions functionally equivalent to amino acids Met129, Asp141, Glu143, Cys223, Leu408, Tyr409, Pro410, Ala485, Tyr497, Arg247, Glu599, and His633 in said 9°N DNA polymerase amino acid sequence 5. The polymerase of claim 1 , 3 or 4 , further comprising mutations. （ｉ）Ｍｅｔ１２９と機能的に等価な位置での前記置換変異が、非極性または疎水性アミノ酸への変異を含み、任意でＭｅｔ１２９と機能的に等価な位置での前記置換変異が、Ａｌａへの変異を含むか、または
（ｉｉ）Ａｓｐ１４１と機能的に等価な位置での前記置換変異が、非極性または疎水性アミノ酸への変異を含み、任意でＡｓｐ１４１と機能的に等価な位置での前記置換変異が、Ａｌａへの変異を含むか、または
（ｉｉｉ）Ｇｌｕ１４３と機能的に等価な位置での前記置換変異が、非極性または疎水性アミノ酸への変異を含み、任意でＧｌｕ１４３と機能的に等価な位置での前記置換変異が、Ａｌａへの変異を含むか、または
（ｉｖ）Ｃｙｓ２２３と機能的に等価な位置での前記置換変異が、極性または非荷電アミノ酸への変異を含み、任意でＣｙｓ２２３と機能的に等価な位置での前記置換変異が、Ｓｅｒへの変異を含むか、または
（ｖ）Ｌｅｕ４０８と機能的に等価な位置での前記置換変異が、非極性または疎水性アミノ酸への変異を含み、任意でＬｅｕ４０８と機能的に等価な位置での前記置換変異が、Ａｌａへの変異を含むか、または
（ｖｉ）Ｔｙｒ４０９と機能的に等価な位置での前記置換変異が、非極性または疎水性アミノ酸への変異を含み、任意でＴｙｒ４０９と機能的に等価な位置での前記置換変異が、Ａｌａへの変異を含むか、または
（ｖｉｉ）Ｐｒｏ４１０と機能的に等価な位置での前記置換変異が、非極性または疎水性アミノ酸への変異を含み、任意でＰｒｏ４１０と機能的に等価な位置での前記置換変異が、Ｉｌｅへの変異を含むか、または
（ｖｉｉｉ）Ａｌａ４８５と機能的に等価な位置での前記置換変異が、非極性または疎水性アミノ酸への変異を含み、任意でＡｌａ４８５と機能的に等価な位置での前記置換変異が、Ｖａｌへの変異を含むか、または
（ｉｘ）Ｔｙｒ４９７と機能的に等価な位置での前記置換変異が、非極性、疎水性、または非荷電アミノ酸への変異を含み、任意でＴｙｒ４９７と機能的に等価な位置での前記置換変異が、Ｇｌｙへの変異を含むか、または
（ｘ）Ａｒｇ２４７と機能的に等価な位置での前記置換変異が、極性または非荷電アミノ酸への変異を含み、任意でＡｒｇ２４７と機能的に等価な位置での前記置換変異が、Ｔｙｒへの変異を含むか、または
（ｘｉ）Ｇｌｕ５９９と機能的に等価な位置での前記置換変異が、極性アミノ酸への変異を含み、任意でＧｌｕ５９９と機能的に等価な位置での前記置換変異が、Ａｓｐへの変異を含むか、または
（ｘｉｉ）Ｈｉｓ６３３と機能的に等価な位置での前記置換変異が、非極性、疎水性、または非荷電アミノ酸への変異を含み、任意でＨｉｓ６３３と機能的に等価な位置での前記置換変異が、Ｇｌｙへの変異を含む、
請求項５に記載のポリメラーゼ。 (i) said substitution mutation at a position functionally equivalent to Met129 comprises a mutation to a non-polar or hydrophobic amino acid, optionally said substitution mutation at a position functionally equivalent to Met129 is to Ala contains mutations in or
(ii) said substitution mutation at a position functionally equivalent to Asp141 comprises a mutation to a non-polar or hydrophobic amino acid, optionally said substitution mutation at a position functionally equivalent to Asp141 comprises a mutation to Ala contains a mutation, or
(iii) said substitution mutation at a position functionally equivalent to Glu143 comprises a mutation to a non-polar or hydrophobic amino acid, optionally said substitution mutation at a position functionally equivalent to Glu143 comprises a mutation to Ala contains a mutation, or
(iv) said substitution mutation at a position functionally equivalent to Cys223 comprises a mutation to a polar or uncharged amino acid, optionally said substitution mutation at a position functionally equivalent to Cys223 is a mutation to Ser contains or
(v) said substitution mutation at a position functionally equivalent to Leu408 comprises a mutation to a non-polar or hydrophobic amino acid, optionally said substitution mutation at a position functionally equivalent to Leu408 comprises a mutation to Ala contains a mutation, or
(vi) said substitution mutation at a position functionally equivalent to Tyr409 comprises a mutation to a non-polar or hydrophobic amino acid, optionally said substitution mutation at a position functionally equivalent to Tyr409 comprises a mutation to Ala contains a mutation, or
(vii) said substitution mutation at a position functionally equivalent to Pro410 comprises a mutation to a non-polar or hydrophobic amino acid, optionally said substitution mutation at a position functionally equivalent to Pro410 comprises a mutation to Ile contains a mutation, or
(viii) said substitution mutation at a position functionally equivalent to Ala485 comprises a mutation to a non-polar or hydrophobic amino acid, optionally said substitution mutation at a position functionally equivalent to Ala485 comprises a mutation to Val contains a mutation, or
(ix) said substitution mutation at a position functionally equivalent to Tyr497 comprises mutation to a non-polar, hydrophobic or uncharged amino acid, optionally said substitution mutation at a position functionally equivalent to Tyr497 is , contains mutations to Gly, or
(x) said substitution mutation at a position functionally equivalent to Arg247 comprises a mutation to a polar or uncharged amino acid, optionally said substitution mutation at a position functionally equivalent to Arg247 is a mutation to Tyr contains or
(xi) said substitution mutation at a position functionally equivalent to Glu599 comprises a mutation to a polar amino acid, optionally said substitution mutation at a position functionally equivalent to Glu599 comprises a mutation to Asp; ,or
(xii) said substitution mutation at a position functionally equivalent to His633 comprises mutation to a non-polar, hydrophobic or uncharged amino acid, optionally said substitution mutation at a position functionally equivalent to His633 is , including mutations to Gly,
The polymerase of claim 5 . 前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中の、Ｔｙｒ４９７と機能的に等価な位置でのアミノ酸置換変異およびＡｒｇ２４７、Ｇｌｕ５９９、またはＨｉｓ６３３と機能的に等価な位置での少なくとも１つのアミノ酸置換変異をさらに含む、請求項１～４のいずれか一項に記載のポリメラーゼ。 further comprising an amino acid substitution mutation at a position functionally equivalent to Tyr497 and at least one amino acid substitution mutation at a position functionally equivalent to Arg247, Glu599, or His633 in said 9°N DNA polymerase amino acid sequence; The polymerase according to any one of claims 1-4 . （ｉ）Ｔｙｒ４９７と機能的に等価な位置での前記置換変異が、非極性、疎水性、または非荷電アミノ酸への変異を含み、任意でＴｙｒ４９７と機能的に等価な位置での前記置換変異が、Ｇｌｙへの変異を含むか、または
（ｉｉ）Ａｒｇ２４７と機能的に等価な位置での前記置換変異が、極性または非荷電アミノ酸への変異を含み、任意でＡｒｇ２４７と機能的に等価な位置での前記置換変異が、Ｔｙｒへの変異を含むか、または
（ｉｉｉ）Ｇｌｕ５９９と機能的に等価な位置での前記置換変異が、極性アミノ酸への変異を含み、任意でＧｌｕ５９９と機能的に等価な位置での前記置換変異が、Ａｓｐへの変異を含むか、または
（ｉｖ）Ｈｉｓ６３３と機能的に等価な位置での前記置換変異が、非極性、疎水性、または非荷電アミノ酸への変異を含み、任意でＨｉｓ６３３と機能的に等価な位置での前記置換変異が、Ｇｌｙへの変異を含む、
請求項７に記載のポリメラーゼ。 (i) said substitution mutation at a position functionally equivalent to Tyr497 comprises mutation to a non-polar, hydrophobic or uncharged amino acid , optionally said substitution mutation at a position functionally equivalent to Tyr497; contains a mutation to Gly, or
(ii) said substitution mutation at a position functionally equivalent to Arg247 comprises a mutation to a polar or uncharged amino acid, optionally said substitution mutation at a position functionally equivalent to Arg247 is a mutation to Tyr contains or
(iii) said substitution mutation at a position functionally equivalent to Glu599 comprises a mutation to a polar amino acid, optionally said substitution mutation at a position functionally equivalent to Glu599 comprises a mutation to Asp; ,or
(iv) said substitution mutation at a position functionally equivalent to His633 comprises mutation to a non-polar, hydrophobic or uncharged amino acid, optionally said substitution mutation at a position functionally equivalent to His633 is , including mutations to Gly,
The polymerase of claim 7 . 前記ポリメラーゼが、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中の、Ｔｙｒ４９７と機能的に等価な位置でのアミノ酸置換変異およびＡｒｇ２４７、Ｇｌｕ５９９、またはＨｉｓ６３３と機能的に等価な位置での少なくとも２つまたは３つのアミノ酸置換変異を含み、任意で前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中のＬｙｓ６２０またはＶａｌ６６１と機能的に等価な位置での少なくとも１つのアミノ酸置換変異をさらに含み、
（ａ）さらに任意でＬｙｓ６２０と機能的に等価な位置での前記置換変異が、極性アミノ酸への変異を含み、任意でＬｙｓ６２０と機能的に等価な位置での前記置換変異が、Ａｒｇへの変異を含むか、または
（ｂ）さらに任意でＶａｌ６６１と機能的に等価な位置での前記置換変異が、極性アミノ酸への変異を含み、
任意でＶａｌ６６１と機能的に等価な位置での前記置換変異が、Ａｓｐへの変異を含む、
請求項１～４、７、および８のいずれか一項に記載のポリメラーゼ。 The polymerase has at least two or three amino acid substitution mutations at positions functionally equivalent to Tyr497 and at positions functionally equivalent to Arg247, Glu599, or His633 in the 9°N DNA polymerase amino acid sequence. comprising amino acid substitution mutations, optionally further comprising at least one amino acid substitution mutation at a position functionally equivalent to Lys620 or Val661 in said 9°N DNA polymerase amino acid sequence;
(a) further optionally the substitution mutation at a position functionally equivalent to Lys620 comprises a mutation to a polar amino acid, and optionally the substitution mutation at a position functionally equivalent to Lys620 is a mutation to Arg contains or
(b) further optionally said substitution mutation at a position functionally equivalent to Val661 comprises mutation to a polar amino acid;
optionally said substitution mutation at a position functionally equivalent to Val661 comprises a mutation to Asp;
The polymerase of any one of claims 1-4 , 7 and 8 . 前記ポリメラーゼが、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中の、Ｔｙｒ４９７と機能的に等価な位置でのアミノ酸置換変異およびＡｒｇ２４７、Ｇｌｕ５９９、Ｈｉｓ６３３、Ｌｙｓ６２０、またはＶａｌ６６１から選択されたアミノ酸と機能的に等価な位置での少なくとも２つ、少なくとも３つ、少なくとも４つ、または少なくとも５つのアミノ酸置換変異を含む、請求項１～４および７～９のいずれか一項に記載のポリメラーゼ。 said polymerase is functionally equivalent to an amino acid substitution mutation at a position functionally equivalent to Tyr497 and an amino acid selected from Arg247, Glu599, His633, Lys620, or Val661 in said 9°N DNA polymerase amino acid sequence The polymerase of any one of claims 1-4 and 7-9 , comprising at least 2, at least 3, at least 4, or at least 5 amino acid substitution mutations at positions. 前記ポリメラーゼが、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中のアミノ酸Ｍｅｔ１２９、Ａｓｐ１４１、Ｇｌｕ１４３、Ｃｙｓ２２３、Ｌｅｕ４０８、Ｔｙｒ４０９、Ｐｒｏ４１０、またはＡｌａ４８５と機能的に等価な位置でのアミノ酸置換変異をさらに含む、請求項１～４および７～９のいずれか一項に記載のポリメラーゼ。 Claim 1, wherein said polymerase further comprises an amino acid substitution mutation at a position functionally equivalent to amino acid Met129, Asp141, Glu143, Cys223, Leu408, Tyr409, Pro410, or Ala485 in said 9°N DNA polymerase amino acid sequence. The polymerase of any one of 4 and 7-9 . ９°Ｎ ＤＮＡポリメラーゼアミノ酸配列配列番号８と少なくとも８０％同一であるアミノ酸配列を含む組換えＤＮＡポリメラーゼであって、前記ＤＮＡポリメラーゼは、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中のＴｈｒ３４９Ｓｅｒと機能的に等価な位置でのアミノ酸置換変異を含む、組換えＤＮＡポリメラーゼ。 A recombinant DNA polymerase comprising an amino acid sequence that is at least 80% identical to the 9°N DNA polymerase amino acid sequence SEQ ID NO:8, wherein said DNA polymerase is functionally equivalent to Thr349Ser in said 9°N DNA polymerase amino acid sequence A recombinant DNA polymerase containing an amino acid substitution mutation at a position. ９°Ｎ ＤＮＡポリメラーゼアミノ酸配列配列番号８と少なくとも８０％同一であるアミノ酸配列を含む組換えＤＮＡポリメラーゼであって、前記ＤＮＡポリメラーゼは、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中のＴｈｒ３４９Ａｓｎと機能的に等価な位置でのアミノ酸置換変異を含む、組換えＤＮＡポリメラーゼ。 A recombinant DNA polymerase comprising an amino acid sequence that is at least 80% identical to the 9°N DNA polymerase amino acid sequence SEQ ID NO: 8, said DNA polymerase being functionally equivalent to Thr349Asn in said 9°N DNA polymerase amino acid sequence A recombinant DNA polymerase containing an amino acid substitution mutation at a position. ９°Ｎ ＤＮＡポリメラーゼアミノ酸配列配列番号８と少なくとも８０％同一であるアミノ酸配列を含む組換えＤＮＡポリメラーゼであって、前記ＤＮＡポリメラーゼは、前記９°Ｎ ＤＮＡポリメラーゼアミノ酸配列中のＴｈｒ３４９Ｌｙｓと機能的に等価な位置でのアミノ酸置換変異を含む、組換えＤＮＡポリメラーゼ。 A recombinant DNA polymerase comprising an amino acid sequence that is at least 80% identical to the 9°N DNA polymerase amino acid sequence SEQ ID NO:8, wherein said DNA polymerase is functionally equivalent to Thr349Lys in said 9°N DNA polymerase amino acid sequence A recombinant DNA polymerase containing an amino acid substitution mutation at a position. 配列番号９～１０のいずれか１つのアミノ酸配列を含むＤＮＡポリメラーゼ。 A DNA polymerase comprising the amino acid sequence of any one of SEQ ID NOS: 9-10 . 請求項１～１５のいずれか一項に定義されるポリメラーゼをコードする核酸分子。 A nucleic acid molecule encoding a polymerase as defined in any one of claims 1-15 . 請求項１６に記載の核酸分子を含む発現ベクター。 17. An expression vector comprising the nucleic acid molecule of claim 16 . 請求項１７に記載のベクターを含む宿主細胞。 A host cell comprising the vector of claim 17 . 以下の成分が相互作用することを可能にすることを含む、修飾ヌクレオチド類をＤＮＡに取り込ませるための方法：
（ｉ）請求項１～１５のいずれか一項に記載のポリメラーゼ、
（ｉｉ）ＤＮＡテンプレート；および
（ｉｉｉ）ヌクレオチド溶液。 A method for incorporating modified nucleotides into DNA comprising allowing the following components to interact:
(i) the polymerase of any one of claims 1-15 ,
(ii) a DNA template; and (iii) a nucleotide solution. 請求項１～１５のいずれか一項に定義されるポリメラーゼ、およびヌクレオチド溶液を含む、ヌクレオチド取込み反応を実施するためのキット。
A kit for performing a nucleotide incorporation reaction comprising a polymerase as defined in any one of claims 1-15 and a nucleotide solution.
JP2020572440A 2018-12-05 2019-12-04 Polymerases, compositions, and methods of use Active JP7527208B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775662P 2018-12-05 2018-12-05
US62/775,662 2018-12-05
PCT/US2019/064524 WO2020117968A2 (en) 2018-12-05 2019-12-04 Polymerases, compositions, and methods of use

Publications (3)

Publication Number Publication Date
JP2022511206A JP2022511206A (en) 2022-01-31
JPWO2020117968A5 true JPWO2020117968A5 (en) 2022-09-13
JP7527208B2 JP7527208B2 (en) 2024-08-02

Family

ID=69137980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572440A Active JP7527208B2 (en) 2018-12-05 2019-12-04 Polymerases, compositions, and methods of use

Country Status (14)

Country Link
US (4) US11001816B2 (en)
EP (1) EP3891275A2 (en)
JP (1) JP7527208B2 (en)
KR (1) KR20210098844A (en)
CN (1) CN112639090A (en)
AU (1) AU2019391093B2 (en)
BR (1) BR112020026655A2 (en)
CA (1) CA3103739A1 (en)
IL (2) IL297994A (en)
MX (1) MX2020013357A (en)
MY (1) MY204767A (en)
SG (1) SG11202012559SA (en)
WO (1) WO2020117968A2 (en)
ZA (1) ZA202007839B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112673098B (en) 2018-10-31 2023-01-06 亿明达股份有限公司 Polymerases, compositions and methods of use
WO2020117968A2 (en) 2018-12-05 2020-06-11 Illumina, Inc. Polymerases, compositions, and methods of use
US11293061B2 (en) 2018-12-26 2022-04-05 Illumina Cambridge Limited Sequencing methods using nucleotides with 3′ AOM blocking group
IL292961B2 (en) 2019-11-27 2024-01-01 Illumina Cambridge Ltd Cyclotetraenes contain dyes and their compounds
US11225688B2 (en) 2019-12-23 2022-01-18 Singular Genomics Systems, Inc. Methods for long read sequencing
US11155858B2 (en) 2019-12-31 2021-10-26 Singular Genomics Systems, Inc. Polynucleotide barcodes for long read sequencing
WO2021216998A1 (en) 2020-04-24 2021-10-28 Singular Genomics Systems, Inc. Modified nucleotides and uses thereof
CN120174072A (en) 2020-06-22 2025-06-20 伊鲁米纳剑桥有限公司 Nucleosides and nucleotides with 3' acetal capping groups
US20220195516A1 (en) 2020-12-17 2022-06-23 Illumina Cambridge Limited Methods, systems and compositions for nucleic acid sequencing
US20220195518A1 (en) 2020-12-22 2022-06-23 Illumina Cambridge Limited Methods and compositions for nucleic acid sequencing
US12054506B2 (en) 2021-03-19 2024-08-06 Singular Genomics Systems, Inc. Reducing agents and uses thereof
CA3215598A1 (en) 2021-05-05 2022-11-10 Michael Callingham Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing
US12139727B2 (en) 2021-06-18 2024-11-12 Element Biosciences, Inc. Engineered polymerases
US12077789B2 (en) * 2021-08-14 2024-09-03 Illumina, Inc. Polymerases, compositions, and methods of use
AU2022424380A1 (en) 2021-12-29 2024-01-18 Illumina, Inc. Methods of nucleic acid sequencing using surface-bound primers
US12006518B2 (en) 2022-02-18 2024-06-11 Element Biosciences, Inc. Engineered polymerases with reduced sequence-specific errors
CA3223115A1 (en) 2022-03-28 2023-10-05 Xiaolin Wu Labeled avidin and methods for sequencing
CA3223125A1 (en) 2022-03-29 2023-10-05 Illumina, Inc. Chromenoquinoline dyes and uses in sequencing
EP4499871A1 (en) 2022-03-30 2025-02-05 Illumina, Inc. Methods for chemical cleavage of surface-bound polynucleotides
EP4499659A1 (en) 2022-03-31 2025-02-05 Illumina, Inc. Nucleosides and nucleotides with 3' vinyl blocking group useful in sequencing by synthesis
EP4499870A1 (en) 2022-03-31 2025-02-05 Illumina, Inc. Compositions and methods for improving sequencing signals
AU2023281871A1 (en) 2022-05-31 2024-11-14 Illumina, Inc Compositions and methods for nucleic acid sequencing
CN119604513A (en) 2022-06-28 2025-03-11 因美纳公司 Fluorescent dyes containing fused tetracyclic biboronic heterocycles and their use in sequencing
EP4594428A2 (en) 2022-09-30 2025-08-06 Illumina, Inc. Compositions and methods for reducing photo damage during sequencing
US20240141427A1 (en) 2022-09-30 2024-05-02 Illumina, Inc. Polymerases, compositions, and methods of use
US20240240217A1 (en) 2022-12-09 2024-07-18 Illumina, Inc. Nucleosides and nucleotides with 3' blocking groups and cleavable linkers
CN119095983A (en) 2022-12-22 2024-12-06 伊路米纳有限公司 Transition metal catalyst compositions and methods for sequencing by synthesis
WO2024137774A1 (en) 2022-12-22 2024-06-27 Illumina, Inc. Palladium catalyst compositions and methods for sequencing by synthesis
EP4642931A1 (en) 2022-12-27 2025-11-05 Illumina, Inc. Methods of sequencing using 3´ allyl blocked nucleotides
CN119452044A (en) 2023-03-29 2025-02-14 因美纳公司 Naphthalimide dyes and their use in nucleic acid sequencing
US20240327909A1 (en) 2023-03-30 2024-10-03 Illumina, Inc. Compositions and methods for nucleic acid sequencing
WO2024249200A1 (en) 2023-05-26 2024-12-05 Illumina, Inc. Methods for preserving methylation status during clustering
WO2024249061A1 (en) 2023-05-31 2024-12-05 Illumina, Inc. Detecting a methylated nucleotide using a quencher
WO2024249591A1 (en) 2023-05-31 2024-12-05 Illumina, Inc. Methods for double-stranded sequencing by synthesis
WO2025049700A1 (en) 2023-08-31 2025-03-06 Illumina, Inc. Compositions and methods for nucleic acid sequencing
WO2025090596A1 (en) 2023-10-26 2025-05-01 Illumina, Inc. 4,5-substituted naphthalimide dyes and uses in nucleic acid sequencing
WO2025106715A1 (en) 2023-11-17 2025-05-22 Illumina, Inc. Conjugated polymers or polymer dots as fluorescent labels
WO2025136890A1 (en) 2023-12-18 2025-06-26 Illumina, Inc. Hydrogel nanoparticles as labeling scaffold in sequencing
WO2025144626A1 (en) 2023-12-28 2025-07-03 Illumina, Inc. Sequencing with single-stranded binding proteins
WO2025144716A1 (en) 2023-12-28 2025-07-03 Illumina, Inc. Nucleotides with enzymatically cleavable 3'-o-glycoside blocking groups for sequencing
WO2025144711A1 (en) 2023-12-29 2025-07-03 Illumina, Inc. Tricyclic polymethine dyes for nucleic acid sequencing
WO2025184226A1 (en) 2024-02-28 2025-09-04 Illumina, Inc. Nucleotides with terminal phosphate capping
WO2025188906A1 (en) 2024-03-08 2025-09-12 Illumina, Inc. Modified adenosine nucleotides
WO2025230914A1 (en) 2024-04-29 2025-11-06 Illumina, Inc. Nucleotides with enzyme-triggered self-immolative linkers for sequencing by synthesis

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA258147A (en) 1926-02-16 W. Pease John Apple paring machine
EP0450060A1 (en) 1989-10-26 1991-10-09 Sri International Dna sequencing
US5756334A (en) 1990-04-26 1998-05-26 New England Biolabs, Inc. Thermostable DNA polymerase from 9°N-7 and methods for producing the same
CA2251643A1 (en) 1996-04-15 1997-10-23 University Of Alberta Synthesis of fluorophore-labeled dna
DE69725076T2 (en) 1996-07-29 2004-04-15 Toyo Boseki K.K. Modified thermostable DNA polymerase and a DNA polymerase composition for the amplification of nucleic acids
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
US6228628B1 (en) 1997-07-09 2001-05-08 Roche Molecular Systems Mutant chimeric DNA polymerase
US5882904A (en) 1997-08-04 1999-03-16 Amersham Pharmacia Biotech Inc. Thermococcus barossii DNA polymerase mutants
US5948666A (en) 1997-08-06 1999-09-07 Diversa Corporation Isolation and identification of polymerases
US20050181440A1 (en) 1999-04-20 2005-08-18 Illumina, Inc. Nucleic acid sequencing using microsphere arrays
JP4150166B2 (en) 1999-05-07 2008-09-17 ロシュ ダイアグノスティックス ゲーエムベーハー High density labeling of DNA using modified polymerases or nucleotides with chromophores and DNA polymerase
US6492161B1 (en) 1999-06-02 2002-12-10 Prokaria Ltd. Bacteriophage RM 378 of a thermophilic host organism
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
US7244559B2 (en) 1999-09-16 2007-07-17 454 Life Sciences Corporation Method of sequencing a nucleic acid
WO2001023411A2 (en) 1999-09-30 2001-04-05 New England Biolabs, Inc. Incorporation of modified nucleotides by archaeon dna polymerases and related methods
US8268605B2 (en) 1999-10-29 2012-09-18 Agilent Technologies, Inc. Compositions and methods utilizing DNA polymerases
WO2001032887A1 (en) 1999-10-29 2001-05-10 Stratagene Compositions and methods utilizing dna polymerases
US20030228616A1 (en) 1999-10-29 2003-12-11 Stratagene DNA polymerase mutants with reverse transcriptase activity
AU1491401A (en) 1999-11-23 2001-06-04 Amersham Pharmacia Biotech Inc. Improving dideoxynucleotide-triphosphate utilization by the hyper-thermophilic dna polymerase from the archaeon pyrococcus furiosus
US6329178B1 (en) 2000-01-14 2001-12-11 University Of Washington DNA polymerase mutant having one or more mutations in the active site
AU2007201277B2 (en) 2000-05-24 2011-10-13 Third Wave Technologies, Inc. Detection of RNA
CN101525660A (en) 2000-07-07 2009-09-09 维西根生物技术公司 An instant sequencing methodology
AU2001279134A1 (en) 2000-07-31 2002-02-13 Maxygen, Inc. Nucleotide incorporating enzymes
EP1354064A2 (en) 2000-12-01 2003-10-22 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
EP1395805A4 (en) 2001-06-11 2005-03-09 Illumina Inc Multiplexed detection methods
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
EP3795577A1 (en) 2002-08-23 2021-03-24 Illumina Cambridge Limited Modified nucleotides
US7595883B1 (en) 2002-09-16 2009-09-29 The Board Of Trustees Of The Leland Stanford Junior University Biological analysis arrangement and approach therefor
US8283148B2 (en) 2002-10-25 2012-10-09 Agilent Technologies, Inc. DNA polymerase compositions for quantitative PCR and methods thereof
GB0321306D0 (en) 2003-09-11 2003-10-15 Solexa Ltd Modified polymerases for improved incorporation of nucleotide analogues
US7315019B2 (en) 2004-09-17 2008-01-01 Pacific Biosciences Of California, Inc. Arrays of optical confinements and uses thereof
US20070048748A1 (en) * 2004-09-24 2007-03-01 Li-Cor, Inc. Mutant polymerases for sequencing and genotyping
GB0509508D0 (en) * 2005-05-10 2005-06-15 Solexa Ltd Improved polymerases
US8623628B2 (en) 2005-05-10 2014-01-07 Illumina, Inc. Polymerases
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
ES2648313T3 (en) 2005-12-22 2017-12-29 Pacific Biosciences Of California, Inc. Polymerases for the incorporation of nucleotide analogs
EP3722409A1 (en) 2006-03-31 2020-10-14 Illumina, Inc. Systems and devices for sequence by synthesis analysis
US7781200B2 (en) 2006-07-14 2010-08-24 Novozymes A/S Polypeptides having lipase activity and polynucleotides encoding same
EP2074211B1 (en) * 2006-09-06 2013-03-13 Medical Research Council DNA polymerases incorporating dye-labelled nucleotide analogues
GB0617575D0 (en) 2006-09-06 2006-10-18 Syngenta Ltd Herbicidal compounds and compositions
WO2008051530A2 (en) 2006-10-23 2008-05-02 Pacific Biosciences Of California, Inc. Polymerase enzymes and reagents for enhanced nucleic acid sequencing
EP4134667B1 (en) 2006-12-14 2025-11-12 Life Technologies Corporation Apparatus for measuring analytes using fet arrays
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
US8349167B2 (en) 2006-12-14 2013-01-08 Life Technologies Corporation Methods and apparatus for detecting molecular interactions using FET arrays
WO2008083393A2 (en) 2006-12-29 2008-07-10 Stratagene California Compositions and methods using split polymerases
US7892797B2 (en) 2007-12-27 2011-02-22 Ge Healthcare Bio-Sciences Corp. Single enzyme system for fast, ultra long PCR
WO2009131919A2 (en) 2008-04-22 2009-10-29 New England Biolabs, Inc. Polymerases for incorporating modified nucleotides
US20100137143A1 (en) 2008-10-22 2010-06-03 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes
WO2010062779A2 (en) 2008-11-03 2010-06-03 Kapabiosystems Modified dna polymerases
WO2010062776A2 (en) 2008-11-03 2010-06-03 Kapabiosystems Chimeric dna polymerases
CA2749693C (en) 2009-01-15 2018-11-06 Hokkaido Mitsui Chemicals Inc. Enzyme preparation containing thermostable dna polymerase, method for producing same, and method for detecting subject organism to be detected
WO2011026194A1 (en) 2009-09-07 2011-03-10 Reproductive Health Science Pty Ltd Nucleic acid extraction
US8965076B2 (en) 2010-01-13 2015-02-24 Illumina, Inc. Data processing system and methods
US20110301041A1 (en) 2010-02-26 2011-12-08 Life Technologies Corporation Modified Proteins and Methods of Making and Using Same
GB201007384D0 (en) 2010-04-30 2010-06-16 Medical Res Council Enzymes
EP3928867B1 (en) 2010-10-27 2024-07-17 Illumina, Inc. Microdevices and biosensor cartridges for biological or chemical analysis and systems and methods for the same
US8921044B2 (en) 2011-05-11 2014-12-30 New England Biolabs, Inc. DNA polymerase variants with reduced exonuclease activity and uses thereof
EP2707481B1 (en) 2011-05-11 2016-07-13 New England Biolabs, Inc. Dna polymerase variants with reduced exonuclease activity and uses thereof
JP6478445B2 (en) * 2012-09-28 2019-03-06 東洋紡株式会社 Modified thermostable DNA polymerase
CA2898459C (en) 2013-03-14 2021-02-02 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
BR112015022448B1 (en) 2013-03-15 2020-12-08 Illumina Cambridge Limited modified nucleotide or nucleoside molecule, methods for preparing the growth of polynucleotide complementary to single-stranded target polynucleotide in sequencing reaction and to determine the sequence of single-stranded target polynucleotide and kit
GB2526261B (en) 2014-04-28 2017-08-02 Gelliner Ltd Encoded cells and cell arrays
ES2788949T3 (en) 2014-06-27 2020-10-23 Illumina Inc Modified polymerases for improved incorporation of nucleotide analogs
US20180216098A1 (en) 2014-08-27 2018-08-02 New England Biolabs, Inc. Synthon Formation
WO2016054096A1 (en) 2014-09-30 2016-04-07 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
EP4006150A1 (en) 2015-09-09 2022-06-01 QIAGEN GmbH Polymerase enzyme
US10662413B2 (en) * 2016-11-01 2020-05-26 Personal Genomics, Inc. Recombinant DNA polymerase for improved incorporation of nucleotide analogues
EP3613851A4 (en) 2017-01-09 2020-07-01 MGI Tech Co., Ltd. RECOMBINANT DNA POLYMERASE
WO2018148724A1 (en) 2017-02-13 2018-08-16 Qiagen Waltham Inc. Polymerase enzyme from pyrococcus furiosus
WO2018148726A1 (en) 2017-02-13 2018-08-16 Qiagen Waltham Inc. Polymerase enzyme from phage t4
US20200002689A1 (en) 2017-02-13 2020-01-02 Qiagen Sciences, Llc Polymerase enzyme from 9°n
WO2018148727A1 (en) 2017-02-13 2018-08-16 Qiagen Waltham Inc. Polymerase enzyme from 9°n
WO2018148723A1 (en) 2017-02-13 2018-08-16 Qiagen Waltham Inc. Polymerase enzyme from pyrococcus abyssi
GB201711219D0 (en) 2017-07-12 2017-08-23 Illumina Cambridge Ltd Short pendant arm linkers for nucleotides in sequencing applications
EP3862427A4 (en) 2018-09-03 2022-04-27 BGI Shenzhen RECOMBINANT KOD POLYMERASE
US11136565B2 (en) 2018-09-11 2021-10-05 Singular Genomics Systems, Inc. Modified archaeal family B polymerases
EP3853358A1 (en) 2018-09-17 2021-07-28 Omniome, Inc. Engineered polymerases for improved sequencing
CN112673098B (en) 2018-10-31 2023-01-06 亿明达股份有限公司 Polymerases, compositions and methods of use
WO2020117968A2 (en) 2018-12-05 2020-06-11 Illumina, Inc. Polymerases, compositions, and methods of use
US11293061B2 (en) 2018-12-26 2022-04-05 Illumina Cambridge Limited Sequencing methods using nucleotides with 3′ AOM blocking group

Similar Documents

Publication Publication Date Title
JPWO2020117968A5 (en)
JPWO2020092830A5 (en)
JP2025013884A5 (en)
CN112639089B (en) Recombinant KOD polymerase
JPWO2020139783A5 (en)
JP2008539750A5 (en)
JP2009542228A5 (en)
KAGAWA et al. Stable structure of thermophilic proton ATPase beta subunit
CN101613680B (en) Moloney murine leukemia virus reverse transcriptase mutant as well as expression method and application thereof
Argos et al. Primary structural relationships may reflect similar DNA replication strategies
CN106467910A (en) L-DNA/L-RNA polymerase and its application
WO2023143123A1 (en) Terminal transferase variant for controllable synthesis of single-stranded dna and use thereof
JP2004533811A5 (en)
CN116589591B (en) Application of MBP (MBP) tag, spy tag or MBP-Spy tandem tag in auxiliary recombinant protein expression
CN108795900B (en) DNA polymerase and preparation method thereof
CN110747191A (en) Polypeptides, chimeric polymerases and their applications
EP3976809A1 (en) Variants of terminal deoxynucleotidyl transferase and uses thereof
JP2020127419A5 (en)
WO2000066722B1 (en) Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
CN118256467B (en) Terminal deoxynucleotidyl transferase variants, nucleic acids and uses
JPWO2020219908A5 (en)
CN115247162B (en) Fusion protein for adenine base editing and application thereof
Fang et al. Investigations on the tobacco necrosis virus D p60 replicase protein
WO2022271548A2 (en) Compositions, methods and systems for the delivery of gene editing material to cells
CN111349623B (en) 9°N DNA polymerase mutant